Modern Esophageal Function Testing and Gastroesophageal Reflux Disease in Morbidly Obese Patients.


Journal

Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714

Informations de publication

Date de publication:
11 2019
Historique:
pubmed: 16 6 2019
medline: 27 5 2020
entrez: 16 6 2019
Statut: ppublish

Résumé

The implementation of high-resolution manometry (HRM) and the Lyon Consensus statement facilitate evaluation of gastroesophageal reflux disease and motility disorders in morbidly obese patients. Therefore, we aimed to investigate prevalence and phenotype of (borderline) GERD and esophageal motility disorders in this population. Consecutive morbidly obese (BMI ≥ 35 kg/m Out of 448 eligible individuals, 147 patients (females = 75, 51%) with a median age of 41.6 (33.4; 52.3) years and a BMI of 44 (40.9; 49.4) kg/m The current gold standard of assessment revealed that the prevalence of esophageal motility disorders and (borderline) GERD is high in the morbidly obese population. Further longitudinal data are needed to delineate the natural course of novel motility disorders like JE in obesity and to identify risk factors for adverse outcomes following bariatric surgery.

Sections du résumé

BACKGROUND
The implementation of high-resolution manometry (HRM) and the Lyon Consensus statement facilitate evaluation of gastroesophageal reflux disease and motility disorders in morbidly obese patients. Therefore, we aimed to investigate prevalence and phenotype of (borderline) GERD and esophageal motility disorders in this population.
METHODS
Consecutive morbidly obese (BMI ≥ 35 kg/m
RESULTS
Out of 448 eligible individuals, 147 patients (females = 75, 51%) with a median age of 41.6 (33.4; 52.3) years and a BMI of 44 (40.9; 49.4) kg/m
CONCLUSIONS
The current gold standard of assessment revealed that the prevalence of esophageal motility disorders and (borderline) GERD is high in the morbidly obese population. Further longitudinal data are needed to delineate the natural course of novel motility disorders like JE in obesity and to identify risk factors for adverse outcomes following bariatric surgery.

Identifiants

pubmed: 31201693
doi: 10.1007/s11695-019-04020-1
pii: 10.1007/s11695-019-04020-1
doi:

Types de publication

Historical Article Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3536-3541

Références

J Clin Gastroenterol. 2003 Sep;37(3):206-15
pubmed: 12960718
Digestion. 2017;95(1):29-35
pubmed: 28052278
Eur J Gastroenterol Hepatol. 1996 Jul;8(7):635-40
pubmed: 8853250
Obes Surg. 1999 Aug;9(4):390-5
pubmed: 10484299
N Engl J Med. 2017 Feb 16;376(7):641-651
pubmed: 28199805
Obes Surg. 2018 Nov;28(11):3586-3594
pubmed: 30047101
Obes Surg. 2002 Feb;12(1):72-6
pubmed: 11868303
Obes Surg. 2004 Jun-Jul;14(6):744-9
pubmed: 15318976
Surg Obes Relat Dis. 2018 Jun;14(6):764-768
pubmed: 29631982
Gut. 2018 Jul;67(7):1351-1362
pubmed: 29437910
Dig Dis Sci. 1999 Nov;44(11):2290-4
pubmed: 10573376
Gastroenterology. 2007 Mar;132(3):883-9
pubmed: 17324403
Neurogastroenterol Motil. 2015 Feb;27(2):160-74
pubmed: 25469569
Dig Dis Sci. 1995 Aug;40(8):1632-5
pubmed: 7648961
Lancet Neurol. 2017 Jun;16(6):465-477
pubmed: 28504110
J Med. 1987;18(3-4):135-46
pubmed: 3480930
J Gastrointest Surg. 2009 Dec;13(12):2219-25
pubmed: 19672666
Gut. 1999 Aug;45(2):172-80
pubmed: 10403727
Sci Rep. 2018 Jul 2;8(1):9949
pubmed: 29967357
Surg Endosc. 2019 Mar;33(3):789-793
pubmed: 30003346
J Gastroenterol Hepatol. 2016 Jun;31(6):1133-40
pubmed: 26670865
Obes Surg. 2016 Oct;26(10):2449-56
pubmed: 26956879
Neurogastroenterol Motil. 2017 Mar;29(3):
pubmed: 27660053
Endosc Int Open. 2016 May;4(5):E585-8
pubmed: 27274539
J Thorac Dis. 2017 May;9(5):E432-E436
pubmed: 28616302
Lancet. 2014 Aug 30;384(9945):766-81
pubmed: 24880830
Obes Surg. 2018 Feb;28(2):313-322
pubmed: 28822052
JAMA. 1999 Oct 27;282(16):1523-9
pubmed: 10546691
Obes Surg. 2004 Aug;14(7):959-66
pubmed: 15329186
Neurogastroenterol Motil. 2018 May;30(5):e13276
pubmed: 29266608

Auteurs

Ivan Kristo (I)

Department of Surgery, Upper GI Research and Service, Comprehensive Cancer Center, Gastroesophageal Tumor Unit, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

Matthias Paireder (M)

Department of Surgery, Upper GI Research and Service, Comprehensive Cancer Center, Gastroesophageal Tumor Unit, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

Gerd Jomrich (G)

Department of Surgery, Upper GI Research and Service, Comprehensive Cancer Center, Gastroesophageal Tumor Unit, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

Daniel M Felsenreich (DM)

Department of Surgery, Metabolic & Bariatric Surgery, Medical University of Vienna, Vienna, Austria.

Milena Nikolic (M)

Department of Surgery, Upper GI Research and Service, Comprehensive Cancer Center, Gastroesophageal Tumor Unit, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

Felix B Langer (FB)

Department of Surgery, Metabolic & Bariatric Surgery, Medical University of Vienna, Vienna, Austria.

Gerhard Prager (G)

Department of Surgery, Metabolic & Bariatric Surgery, Medical University of Vienna, Vienna, Austria.

Sebastian F Schoppmann (SF)

Department of Surgery, Upper GI Research and Service, Comprehensive Cancer Center, Gastroesophageal Tumor Unit, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. sebastian.schoppmann@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH